The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Current treatments are estimated to only reduce about one-third of the disease burden of depressive disorders. Prevention may be an alternative strategy to further reduce the disease burden of ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...